Company profile
Nuvation Bio Inc.
NYSE:NUVBBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TALETRECTINIB ADIPATE | approved | — | 0 | — |
| TALETRECTINIB | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02279433 | phase1 | completed | 2014-09-01 | 2019-03-01 | Nuvation Bio Inc. | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
| NCT06564324 | phase3 | recruiting | 2024-11-27 | 2029-01-01 | Nuvation Bio Inc. | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients |
| NCT05357820 | phase1 | completed | 2021-07-19 | 2021-12-03 | Nuvation Bio Inc. | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK |
| NCT04395677 | phase2 | active_not_recruiting | 2020-07-07 | 2024-06-07 | Nuvation Bio Inc. | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene |
| NCT05357911 | phase1 | completed | 2021-07-13 | 2021-08-20 | Nuvation Bio Inc. | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 219713 | NDA | NUVATION BIO INC | ||||
Loading… | ||||||